Background: The temporomandibular joint (TMJ) is one of the most complex joints in the body. Temporomandibular disorders (TMD) are among the most troublesome disorders for patients, as they can cause pain, affect oral functions and disturb dentists on the level of diagnosis and treatment. The most common symptoms of temporomandibular joint disorders are articulated sounds (such as clicking or TMJ crepitation), joint pain in comfort and function situations (jaw movements), pain or strain in masseter and jaw muscles and or restricted mandibular movements. One of the most modern biocompatible substances used to treat joint disorders, including the TMJ, is platelet-rich plasma (PRP) and injectable platelet-rich fibrin (I-PRF). This study aims to evaluate the efficacy of platelet-rich fibrin (I-PRF) intra-articular injections in managing internal derangements of temporomandibular.
Methods: Twenty patients suffering from a unilateral click due to temporomandibular disorders were individually injected with 1 mL of (I-PRF) twice 1 week apart into the superior joint space of the TMJ with the internal disorder. Data were recorded and evaluated by the Helkimo index. This evaluation was conducted three times; 1 week after the first injection, 1 week after the second injection, and 6 months after the first injection.
Results: The clicking disappeared entirely in 14 out of 20 patients after 1 week of getting the first injection, and in all patients after 1 week of getting the second injection, and returned to two of them after a six-month since the first injection.
Conclusion: Preliminary results showed the efficacy of the Injectable Platelet-Rich Fibrin (I-PRF) in managing articular clicking in patients with internal disorders of the temporomandibular joint. Injectable Platelet Rich Fibrin has significant clinical efficacy in treating the articular clicking resulting from internal temporomandibular joint disorders.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9106792 | PMC |
http://dx.doi.org/10.1186/s12891-022-05421-7 | DOI Listing |
J Contemp Dent Pract
September 2024
Department of Periodontology, Narsinhbhai Patel Dental College and Hospital, Sankalchand Patel University, Visnagar, Gujarat, India.
Aim: This study aims to evaluate the impact of platelet-rich fibrin (PRF) and platelet-rich plasma (PRP) on pain, swelling, trismus, soft tissue healing and bone regeneration following mandibular third molar extraction.
Material And Methods: A systematic review was conducted from a period of January 2014 to June 2024 using PRISMA guidelines. The search strategy included databases such as Scopus, PubMed, Google Scholar, and Cochrane Central Register of Controlled Trials, using key terms related to "PRF", "PRP", oral surgery, and third molars.
J Contemp Dent Pract
September 2024
Department of Orthodontics and Dentofacial Orthopedics, Chettinad Dental College & Research Institute, Chengalpet, Tamil Nadu, India.
Aim: This study intended to comprehend the effects of injectable platelet-rich fibrin (i-PRF) on anchor loss and space closure rates during the retraction phase of orthodontic treatment.
Materials And Methods: Twenty-four participants with malocclusion, necessitating extractions and space closure during orthodontic treatment, were enrolled and divided into two groups ( = 12 participants) group A: the experimental group was administered i-PRF on the maxilla/mandible, while group B: the control group did not. Measurements of the rate of space closure, anchor loss, and salivary enzyme activity were done before retraction (T0), after three weeks (T1), after six weeks (T2), and after nine weeks (T3).
J Adv Periodontol Implant Dent
September 2024
Department of Periodontics, Saveetha Dental College & Hospitals, Saveetha Institute of Medical and Technical Sciences, Chennai, Tamilnadu, India.
Background: The vehicle in a local drug delivery (LDD) system plays a vital role in delivering the active drug component at the diseased site. Liquid/injectable platelet-rich fibrin (i-PRF), an autologous fibrin matrix, might be used as a vehicle to enmesh drugs and deliver locally at the periodontally diseased sites. This study evaluated the efficacy of the drug (ciprofloxacin [Cip])-loaded i-PRF as a LDD system adjunct to subgingival debridement in subjects with periodontal pockets.
View Article and Find Full Text PDFGrowth Factors
December 2024
Department of Oral and Maxillofacial Surgery/Oral Pathology, Amsterdam University Medical Centers and Academic Centre for Dentistry Amsterdam (ACTA), Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Since its introduction in 2001, multiple platelet-rich fibrin (PRF) centrifugation protocols have emerged, but the variations in growth factor release that result from these protocols remain unclear. This review aimed to evaluate growth factor release across three PRF protocols: leukocyte-PRF (L-PRF), advanced-PRF (A-PRF/+), and injectable-PRF (i-PRF). A comprehensive search was conducted using the MEDLINE and Embase databases, identifying 14 studies that met the inclusion criteria.
View Article and Find Full Text PDFWiad Lek
December 2024
PROVINCIAL HOSPITAL NAMED AFTER SAINT LUKE, TARNOW, POLAND.
Injectable platelet-rich fibrin (i-PRF) is a novel platelet concentrate that has been employed in dentistry with the objective of promoting tissue regeneration and healing. In contrast to platelet-rich plasma (PRP), i-PRF is more straightforward to handle, more cost-effective, and free from anticoagulants, which reduces biochemical alterations. The i-PRF procedure was developed in 2014 by adjusting the centrifugation forces.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!